# US 2024/0319178 A1 · Compounds, kits, and methods for bead-based detection of anti-microbe antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0319178 A1
- Document ID: US20240319178A1
- Status: Published application
- Kind: A1
- Application number: 18/270,429
- Filed: 2021-12-29
- Published: 2024-09-26
- Earliest claimed: 2020-12-30
- Assignees: Quest Diagnostics Investments Incorporated
- Applicants: Quest Diagnostics Investments LLC
- Inventors: Mary Lapé Nixon
- Web page: https://patentgrep.com/patent/US20240319178A1

## CPC

- G01N 33/5765: {Hepatitis delta antigen}
- G01N 33/54313: {the carrier being characterised by its particulate form}
- G01N 33/545: Synthetic resin
- G01N 33/56911: {Bacteria}
- G01N 2333/08: RNA viruses
- G01N 2333/20: from Spirochaetales (O), e.g. Treponema, Leptospira
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates generally an immunoassay platform that utilizes a bead-based system to detect the presence or absence of antibodies in a test sample. The disclosed platform relates to methods and kits and can be used to detect the presence, absence, or exposure to Borrelia miyamotoi or Hepatitis D virus (HDV), or other pathogens or microbes of interest in a subject.

## Claims

### Claim 1

A method of determining exposure of a subject to a pathogen or microbe, comprising (i) incubating a liquid biological sample obtained from a subject with a bead particle comprising a core bead coupled to a plurality of antibodies bound to an antigen derived from a pathogen or microbe of interest, such that the antigen is presented on the outside of the bead particle and any antibodies in the liquid biological sample that recognize the antigen can bind to the bead particle; (ii) washing the bead particle; (iii) incubating the bead particle with a detectably labeled antibody that binds to an antibody of the species of the subject; and determining the presences or absence of the detectably labeled antibody, wherein the presence of the detectable label indicates the subject was exposed to the pathogen or microbe of interest and the absence of the detectable label indicates the subject was not exposed to the pathogen or microbe of interest.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the detectably labeled antibody specifically binds to IgG and/or IgM.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the detectable label is selected from among a fluorophore, a pigment, a radioactive isotope, a chemiluminescent molecule, a chromophore, an electron dense label, an enzyme, a dye, a metal, biotin, avidin, streptavidin, and a hapten.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the pathogen or microbe of interest is a virus, bacteria, or fungi.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The method of any one of claims 1-5, wherein the antibodies coupled to the core bead are anti-His antibodies and the antigen is His-tagged.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the antigen was produced recombinately from a bacterial host.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the core bead is a polystyrene microparticle.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the liquid biological sample is selected from among blood, serum, and plasma.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the liquid biological sample is diluted serum.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the amount of the detectable label determined to be present in the liquid biological sample correlates to the amount of anti-pathogen or anti-microbe IgG and/or IgM in the liquid biological sample.

### Claim 12

A bead particle comprising a microparticle coupled to at least one antibody or a plurality or antibodies bound to an antigen derived from a pathogen or microbe of interest; wherein the antigen comprises a tag sequence and wherein the antibody or antibodies specifically bind to the tag sequence.

### Claim 13 (depends on 12)

The bead particle of claim 12, wherein the microparticle is a polystyrene microparticle.

### Claim 14 (depends on 12, 13)

The bead particle of claim 12 or 13, wherein the pathogen or microbe of interest is a virus, bacteria, or fungi.

### Claim 15 (depends on 12, 13)

The bead particle of claim 12 or 13, wherein the tag sequence is a His-tag.

### Claim 16 (depends on 12, 13, 14, 15)

The bead particle of any one of claims 12-15, wherein the antigen was produced recombinately from a bacterial host.

### Claim 17 (depends on 12, 13, 14, 15, 16)

A kit comprising the bead particle of any one of claims 12-16.

### Claim 18 (depends on 17)

The kit of claim 17 further comprising a detectably labeled antibody that specifically binds to IgG and/or IgM, wherein the IgG and/or IgM are, optionally, human IgG and/or human IgM.

### Claim 19 (depends on 18)

The kit of claim 18, wherein the detectably labeled antibody binds to human IgG and/or IgM.

### Claim 20 (depends on 18, 19)

The kit of claim 18 or 19, wherein the detectable label is selected from among a fluorophore, a pigment, a radioactive isotope, a chemiluminescent molecule, a chromophore, an electron dense label, an enzyme, a dye, a metal, biotin, avidin, streptavidin, and a hapten.

### Claim 21

A method of determining exposure of a subject to Borrelia miyamotoi, comprising (i) incubating a liquid biological sample obtained from a subject with a bead particle comprising a core bead coupled to a plurality of antibodies bound to a B. miyamotoi glycerophosphodiester phosphodiesterase (glpQ), such that any anti-glpQ antibodies in the liquid biological sample can bind to the glpQ on the bead particle; (ii) washing the bead particle; (iii) incubating the bead particle with a detectably labeled antibody that binds to an antibody of the species of the subject; and determining the presences or absence of the detectably labeled antibody, wherein the presence of the detectable label indicates the subject was exposed to B. miyamotoi and the absence of the detectable label indicates the subject was not exposed to B. miyamotoi.

### Claim 22 (depends on 21)

The method of claim 21, wherein the subject is a human.

### Claim 23 (depends on 21, 22)

The method of claim 21 or 22, wherein the detectably labeled antibody specifically binds to IgG and/or IgM.

### Claim 24 (depends on 21, 22, 23)

The method of any one of claims 21-23, wherein the detectable label is selected from among a fluorophore, a pigment, a radioactive isotope, a chemiluminescent molecule, a chromophore, an electron dense label, an enzyme, a dye, a metal, biotin, avidin, streptavidin, and a hapten.

### Claim 25 (depends on 21, 22, 23, 24)

The method of any one of claims 21-24, wherein the antibodies bound to the B. miyamotoi glpQ specifically bind to B. miyamotoi glpQ.

### Claim 26 (depends on 21, 22, 23, 24)

The method of any one of claims 21-24, wherein the antibodies bound to the B. miyamotoi glpQ are anti-histidine antibodies and the B. miyamotoi glpQ is His-tagged.

### Claim 27 (depends on 21, 22, 23, 24, 25, 26)

The method of any one of claims 21-26, wherein the B. miyamotoi glpQ was produced recombinately from a bacterial host.

### Claim 28 (depends on 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 21-27, wherein the core bead is a polystyrene microparticle.

### Claim 29 (depends on 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 21-28, wherein the liquid biological sample is selected from among blood, serum, and plasma.

### Claim 30 (depends on 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 21-28, wherein the liquid biological sample is diluted serum.

### Claim 31 (depends on 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 21-30, wherein the amount of the detectable label determined to be present in the liquid biological sample correlates to the amount of anti-B. miyamotoi IgG and/or IgM in the liquid biological sample.

### Claim 32

A bead particle comprising a microparticle coupled to a plurality of antibodies bound to a B. miyamotoi glycerophosphodiester phosphodiesterase (glpQ).

### Claim 33 (depends on 32)

The bead particle of claim 32, wherein the microparticle is a polystyrene microparticle.

### Claim 34 (depends on 32, 33)

The bead particle of claim 32 or 33, wherein the antibodies bound to the B. miyamotoi glpQ specifically bind to B. miyamotoi glpQ.

### Claim 35 (depends on 32, 33)

The bead particle of claim 32 or 33, wherein the antibodies bound to the B. miyamotoi glpQ are anti-histidine antibodies and the B. miyamotoi glpQ is His-tagged.

### Claim 36 (depends on 32, 33, 34, 35)

The bead particle of any one of claims 32-35, wherein the B. miyamotoi glpQ was produced recombinately from a bacterial host.

### Claim 37 (depends on 32, 33, 34, 35, 36)

A kit comprising the bead particle of any one of claims 32-36.

### Claim 38 (depends on 37)

The kit of claim 37 further comprising a detectably labeled antibody that specifically binds to IgG and/or IgM, wherein the IgG and/or IgM are, optionally, human IgG and/or human IgM.

### Claim 39 (depends on 38)

The kit of claim 38, wherein the detectably labeled antibody binds to human IgG and/or IgM.

### Claim 40 (depends on 38, 39)

The kit of claim 38 or 39, wherein the detectable label is selected from among a fluorophore, a pigment, a radioactive isotope, a chemiluminescent molecule, a chromophore, an electron dense label, an enzyme, a dye, a metal, biotin, avidin, streptavidin, and a hapten.

### Claim 41

A method of determining exposure of a subject to hepatitis D virus (HDV), comprising (i) incubating a liquid biological sample obtained from a subject with a bead particle comprising a core bead coupled to a plurality of antibodies bound to a HDV antigen, such that any antibodies in the liquid biological sample that are capable of binding to the HDV antigen can bind to the HDV antigen on the bead particle; (ii) washing the bead particle; (iii) incubating the bead particle with a detectably labeled antibody that binds to an antibody of the species of the subject; and determining the presences or absence of the detectably labeled antibody, wherein the presence of the detectable label indicates the subject was exposed to HDV and the absence of the detectable label indicates the subject was not exposed to HDV.

### Claim 42 (depends on 41)

The method of claim 41, wherein the subject is a human.

### Claim 43 (depends on 41, 42)

The method of claim 41 or 42, wherein the detectably labeled antibody specifically binds to IgG and/or IgM.

### Claim 44 (depends on 41, 42, 43)

The method of any one of claims 41-43, wherein the detectable label is selected from among a fluorophore, a pigment, a radioactive isotope, a chemiluminescent molecule, a chromophore, an electron dense label, an enzyme, a dye, a metal, biotin, avidin, streptavidin, and a hapten.

### Claim 45 (depends on 41, 42, 43, 44)

The method of any one of claims 41-44, wherein the antibodies bound to the HDV antigen specifically bind to the HDV antigen.

### Claim 46 (depends on 41, 42, 43, 44)

The method of any one of claims 41-44, wherein the antibodies bound to the HDV antigen are anti-histidine antibodies and the HDV antigen is His-tagged.

### Claim 47 (depends on 41, 42, 43, 44, 45, 46)

The method of any one of claims 41-46, wherein the HDV antigen was produced recombinately from a bacterial host.

### Claim 48 (depends on 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 41-47, wherein the core bead is a polystyrene microparticle.

### Claim 49 (depends on 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 41-48, wherein the liquid biological sample is selected from among blood, serum, and plasma.

### Claim 50 (depends on 41, 42, 43, 44, 45, 46, 47, 48)

The method of any one of claims 41-48, wherein the liquid biological sample is diluted serum.

### Claim 51 (depends on 41, 42, 43, 44, 45, 46, 47, 48, 49, 50)

The method of any one of claims 41-50, wherein the amount of the detectable label determined to be present in the liquid biological sample correlates to the amount of anti-HDV IgG and/or IgM in the liquid biological sample.

### Claim 52

A bead particle comprising a microparticle coupled to a plurality of antibodies bound to a hepatitis D virus (HDV) antigen.

### Claim 53 (depends on 52)

The bead particle of claim 52, wherein the microparticle is a polystyrene microparticle.

### Claim 54 (depends on 52, 53)

The bead particle of claim 52 or 53, wherein the antibodies bound to HDV antigen specifically bind to the HDV antigen.

### Claim 55 (depends on 52, 53)

The bead particle of claim 52 or 53, wherein the antibodies bound to the HDV antigen are anti-histidine antibodies and the HDV antigen is His-tagged.

### Claim 56 (depends on 52, 53, 54, 55)

The bead particle of any one of claims 52-55, wherein the HDV antigen was produced recombinately from a bacterial host.

### Claim 57 (depends on 52, 53, 54, 55, 56)

A kit comprising the bead particle of any one of claims 52-56.

### Claim 58 (depends on 57)

The kit of claim 57 further comprising a detectably labeled antibody that specifically binds to IgG and/or IgM, wherein the IgG and/or IgM are, optionally, human IgG and/or human IgM.

### Claim 59 (depends on 58)

The kit of claim 58, wherein the detectably labeled antibody binds to human IgG and/or IgM.

### Claim 60 (depends on 58, 59)

The kit of claim 58 or 59, wherein the detectable label is selected from among a fluorophore, a pigment, a radioactive isotope, a chemiluminescent molecule, a chromophore, an electron dense label, an enzyme, a dye, a metal, biotin, avidin, streptavidin, and a hapten.
